Type 2 Diabetes Mellitus MedDRA version: 7.0 Level: LLT Classification code 10045242
Conditions
Interventions
Pharmaceutical Form:
Sponsors
Merck & Co., Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: a. Patients with type 2 diabetes who had only been treated with metformin monotherapy and initiated combination therapy with either a sulfonylurea or a glitazone three years prior to study enrollment Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: a. Diabetes caused by genetic disorders, recent surgery, pharmaceutical products, malnutrition, infections, pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Main objective : This observational, outcomes research trial will assess level of glycemic control in real life practice settings in patients with type 2 diabetes who had been treated with metformin monotherapy and initiated combination therapy with either a sulfonylurea or a glitazone three years prior to study enrolment, according to treatment goals recommended by national and international clinical practice guidelines ;Secondary Objective: To describe factors associated with adequate glycemic control such as patient, treatment, and physician characteristics. ;Primary end point(s): Proportion of patients with adequate glycemic control defined by treatment goals recommended by national and international clinical practice guidelines | — |
Countries
Finland
Outcome results
None listed